메뉴 건너뛰기




Volumn 147, Issue 2, 2014, Pages 401-405

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

Author keywords

BRCA1; Breast cancer; Neoadjuvant cisplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

EID: 84929992639     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3100-x     Document Type: Article
Times cited : (246)

References (21)
  • 1
    • 41649102048 scopus 로고    scopus 로고
    • Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    • Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 10:1275–1281
    • (2008) J Clin Oncol , vol.10 , pp. 1275-1281
    • Liedtke, C.1    Mazouni, C.2    Hess, K.R.3
  • 2
    • 0033400828 scopus 로고    scopus 로고
    • Genetic analysis of BRCA1 function in a defined tumor cell line
    • COI: 1:CAS:528:DC%2BD3cXislaqug%3D%3D, PID: 10635334
    • Scully R, Ganesan S, Vlasakova K et al (1999) Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4:1093–1099
    • (1999) Mol Cell , vol.4 , pp. 1093-1099
    • Scully, R.1    Ganesan, S.2    Vlasakova, K.3
  • 3
    • 0038147067 scopus 로고    scopus 로고
    • BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
    • COI: 1:CAS:528:DC%2BD3sXivFShsr0%3D, PID: 12698198
    • Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291
    • (2003) Br J Cancer , vol.88 , pp. 1285-1291
    • Tassone, P.1    Tagliaferri, P.2    Perricelli, A.3
  • 4
    • 0032486752 scopus 로고    scopus 로고
    • Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
    • COI: 1:CAS:528:DyaK1cXlsVOrs78%3D, PID: 9701363
    • Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1138-1145
    • Lakhani, S.R.1    Jacquemier, J.2    Sloane, J.P.3
  • 5
    • 12144290945 scopus 로고    scopus 로고
    • Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type
    • COI: 1:CAS:528:DC%2BD2cXisVGlu7c%3D, PID: 15041722
    • Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034
    • (2004) Clin Cancer Res , vol.10 , pp. 2029-2034
    • Foulkes, W.D.1    Metcalfe, K.2    Sun, P.3
  • 6
    • 37549026190 scopus 로고    scopus 로고
    • BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials
    • COI: 1:CAS:528:DC%2BD2sXhsVCktrzL, PID: 18094417
    • Tilanus-Linthorst MM, Obdeijn IM, Hop WC et al (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357–7362
    • (2007) Clin Cancer Res , vol.13 , pp. 7357-7362
    • Tilanus-Linthorst, M.M.1    Obdeijn, I.M.2    Hop, W.C.3
  • 7
    • 85010791733 scopus 로고    scopus 로고
    • A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
    • COI: 1:CAS:528:DC%2BD2cXnsl2hsw%3D%3D, PID: 14680495
    • Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17
    • (2004) Breast Cancer Res , vol.6 , pp. R8-R17
    • Robson, M.E.1    Chappuis, P.O.2    Satagopan, J.3
  • 8
    • 34447303102 scopus 로고    scopus 로고
    • Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations
    • COI: 1:CAS:528:DC%2BD2sXns12qsrk%3D, PID: 17625123
    • Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115–123
    • (2007) N Engl J Med , vol.357 , pp. 115-123
    • Rennert, G.1    Bisland-Naggan, S.2    Barnett-Griness, O.3
  • 9
    • 84874665352 scopus 로고    scopus 로고
    • Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
    • COI: 1:CAS:528:DC%2BC3sXjsFOht7g%3D, PID: 23381743
    • Narod SA, Metcalfe K, Lynch HT et al (2013) Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 138:273–279
    • (2013) Breast Cancer Res Treat , vol.138 , pp. 273-279
    • Narod, S.A.1    Metcalfe, K.2    Lynch, H.T.3
  • 11
    • 0141954010 scopus 로고    scopus 로고
    • BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis
    • Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 6319:6221–6228
    • (2003) Cancer Res , vol.6319 , pp. 6221-6228
    • Quinn, J.E.1    Kennedy, R.D.2    Mullan, P.B.3
  • 12
    • 0034604716 scopus 로고    scopus 로고
    • The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
    • COI: 1:CAS:528:DC%2BD3cXls12lsrk%3D, PID: 10843985
    • Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903
    • (2000) J Biol Chem , vol.275 , pp. 23899-23903
    • Bhattacharyya, A.1    Ear, U.S.2    Koller, B.H.3    Weichselbaum, R.R.4    Bishop, D.K.5
  • 13
    • 33646409883 scopus 로고    scopus 로고
    • BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance
    • Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F (2003) BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001–1007
    • (2003) Cell Cycle , vol.5 , pp. 1001-1007
    • Chabalier, C.1    Lamare, C.2    Racca, C.3    Privat, M.4    Valette, A.5    Larminat, F.6
  • 14
    • 75749143502 scopus 로고    scopus 로고
    • Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy
    • COI: 1:CAS:528:DC%2BC3cXivFart74%3D, PID: 20008645
    • Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379
    • (2010) J Clin Oncol , vol.28 , pp. 375-379
    • Byrski, T.1    Gronwald, J.2    Huzarski, T.3
  • 15
    • 2942572799 scopus 로고    scopus 로고
    • A high proportion of founder BRCA1 mutations in Polish breast cancer families
    • PID: 15146557
    • Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686
    • (2004) Int J Cancer , vol.110 , pp. 683-686
    • Górski, B.1    Jakubowska, A.2    Huzarski, T.3
  • 16
    • 84939922983 scopus 로고    scopus 로고
    • National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 3, June 10, 2004 update. Bethesda, MD, National Cancer Institute
    • NCI (2003) National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 3, June 10, 2004 update. Bethesda, MD, National Cancer Institute, National Institutes of Health
    • (2003) National Institutes of Health
  • 17
    • 84901587677 scopus 로고    scopus 로고
    • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
    • von Minckwitz G, Schneeweiss A, Loibl S (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756
    • (2014) Lancet Oncol , vol.15 , pp. 747-756
    • von Minckwitz, G.1    Schneeweiss, A.2    Loibl, S.3
  • 18
    • 84939922984 scopus 로고    scopus 로고
    • Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
    • Sikov WM, Berry DA, Perou CM, Singh B, et al (2013) Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). In: San Antoniou Breast Cancer Conference 2013 (abstracts S-501)
    • (2013) In: San Antoniou Breast Cancer Conference 2013 (abstracts S-501)
    • Sikov, W.M.1    Berry, D.A.2    Perou, C.M.3    Singh, B.4
  • 19
    • 77949908546 scopus 로고    scopus 로고
    • Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    • COI: 1:CAS:528:DC%2BC3cXktF2ltLk%3D, PID: 20100965
    • Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145–1153
    • (2010) J Clin Oncol , vol.28 , pp. 1145-1153
    • Silver, D.P.1    Richardson, A.L.2    Eklund, A.C.3
  • 20
    • 34447333123 scopus 로고    scopus 로고
    • Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    • COI: 1:STN:280:DC%2BD2s3ns1Kmsg%3D%3D, PID: 17293601
    • Mazouni C, Kau SW, Frye D et al (2007) Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18:874–880
    • (2007) Ann Oncol , vol.18 , pp. 874-880
    • Mazouni, C.1    Kau, S.W.2    Frye, D.3
  • 21
    • 84887094325 scopus 로고    scopus 로고
    • Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer
    • PID: 23940229
    • Huzarski T, Byrski T, Gronwald J et al (2013) Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196. doi:10.1200/JCO.2012.45.3571
    • (2013) J Clin Oncol , vol.31 , pp. 3191-3196
    • Huzarski, T.1    Byrski, T.2    Gronwald, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.